The Investigation of Vitamin D and Menstrual Cycles Trial (the inVitD Trial): A clinical trial of vitamin D supplementation on the hypothalamic-pituitary-ovarian axis
Recommended Citation
Klawans MR, Kohrman O, Braxton Jackson W, 2nd, Jackson CL, Metz CN, Wegienka G, Motsinger-Reif A, Steiner AZ, Baird DD, Sandler DP, and Jukic AMZ. The Investigation of Vitamin D and Menstrual Cycles Trial (the inVitD Trial): A clinical trial of vitamin D supplementation on the hypothalamic-pituitary-ovarian axis. Contemp Clin Trials 2026;160:108176.
Document Type
Article
Publication Date
1-1-2026
Publication Title
Contemp Clin Trials
Keywords
Adult, Female, Humans, Young Adult, Cholecalciferol, Dietary Supplements, Double-Blind Method, Hypothalamo-Hypophyseal System, Luteinizing Hormone, Menstrual Cycle, Multicenter Studies as Topic, Ovary, Progesterone, Randomized Controlled Trials as Topic, Vitamin D, Vitamin D Deficiency, Vitamins, Clinical Trials, Phase II as Topic
Abstract
BACKGROUND: While there is evidence that vitamin D deficiency is associated with long menstrual cycles, delayed ovulation, and reduced fertility, it is yet unknown if increasing vitamin D levels can regulate menstrual cycles, and thus possibly improve fertility. The primary objective of this randomized clinical trial (RCT) is to test the hypothesis that vitamin D supplementation influences the hypothalamic-pituitary-ovarian axis.
METHODS: This two-site RCT (NCT05050916) required participants to be aged 19-40 years old, having spontaneous menstrual cycles, and without certain chronic diseases or contraindications for vitamin D supplementation. At baseline participants provided information on their demographics and health history. Blood was drawn at the first clinic visit after which participants collected daily urine samples for one menstrual cycle (phase 1). Those with a 25-hydroxyvitamin D level less than 20 ng/ml ("low") received cholecalciferol supplementation (randomized to either 4200 IU/week or 50,000 IU/week). A random sample of those without low vitamin D received placebo. Supplement (or placebo) was taken for three menstrual cycles which included collection of daily urine samples and home ovulation testing (phase 2). Participants collected self-administered vaginal and oral swabs and a subset collected menstrual effluent samples. Finally, participants kept a daily menstrual diary and weekly behavior diaries. The primary endpoints were mid-luteal progesterone, rate of estrogen rise, and pre-ovulatory luteinizing hormone.
DISCUSSION: Findings from this RCT will provide insight into the relationship between vitamin D supplementation and menstrual cycle hormones. Vitamin D shows promise as a low-cost, non-hormonal intervention to regulate menstrual cycles.
Medical Subject Headings
Adult; Female; Humans; Young Adult; Cholecalciferol; Dietary Supplements; Double-Blind Method; Hypothalamo-Hypophyseal System; Luteinizing Hormone; Menstrual Cycle; Multicenter Studies as Topic; Ovary; Progesterone; Randomized Controlled Trials as Topic; Vitamin D; Vitamin D Deficiency; Vitamins; Clinical Trials, Phase II as Topic
PubMed ID
41352534
Volume
160
First Page
108176
Last Page
108176
